Best practice is to use a spacer

Carton Doubles As
A Spacer

Our patented innovation enables the carton/box to be utilised as a Spacer, enabling better compliance, delivery and ease of use.

As stated by GINA (Global Initiative for Asthma), use of a Spacer improves delivery and with an Inhaled Corticosteroid (ICS) reduces the potential for side-effects.

Global Strategy for Asthma Management and Prevention (2022 update) p.89 https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf
This low-cost solution will assist patients:

    • In emergencies
    • With better medicine delivery
    • Reduced side effects
    • Compliance with best practice
    • Reduced additional costs

Know More About the MDI PLUS Spacer.

Peer-reviewed Articles

Balancing efficacy and portability: comparative
in vitro/in vivo evaluation of MDI PLUS® versus
AeroChamber2go™ spacers for aerosol delivery

Ahmed H. M. Sobh, Marwa Mohsen, Ahmed M. Abdelfattah, Mohamed E. A.
Abdelrahim & Basma M. E. Mohamed

Published online: 01 Sep 2025

Comparative evaluation of a novel card-based spacer (MDI PLUS®) versus traditional aerochamber plus®: In-vivo and ex-vivo bioavailability study

Assessment of Emergency Spacers Versus Traditional Spacers, An In-Vitro Model for Aerosol Delivery

Omar Ahmed Sayed, Mohamed E.A. Abdelrahim, Nabila Ibrahim Laz & Haitham Saeed

Research Article, Received 03 January 2025, Accepted 21 April 2025, Published: 16 May 2025

Practical Strategies to Improve Asthma Control in Resource-Limited Settings

Haitham Saeed, Hasnaa Osama, Basma M.E. Mohamed, Wesam G. Ammari and Mohamed E.A. Abdelrahim

Evaluation of a cardboard-based Spacer for enhancing aerosol delivery from pressurized metered dose inhalers

Haitham Saeed, PhD ,Wesam G. Ammari, PhD ,Hasnaa Osama, PhD ,Ahmed M. Abdelfattah, MSc ,Mohamed E. A. Abdelrahim, PhD &Basma M. E. Mohamed, PhD

Received 13 Oct 2024, Accepted 03 Feb 2025, Published online: 12 Feb 2025

MDI PLUS – Innovation and Simplicity

What are Spacers?

Spacers, also known as holding chambers or inhaler chambers, are add-on devices used with pressurised metered-dose inhalers (pMDIs) to enhance medication delivery and coordination during inhalation.

These devices, commonly made of plastic, act as an intermediate chamber that holds the medication released from the pMDI, allowing patients to inhale at their own pace and facilitating more of the drug reaching the lungs.

MDI PLUS Manufacturer Benefits

R

Low-cost Primary Pack Spacer

MDI PLUS is a low-cost Spacer alternative as there is little cost added to the existing required packaging.

R

Sustainability

MDI PLUS creates a Reuse for the carton packaging and helps to meet CSR commitments.

R

Best Practice

The MDI PLUS carton Spacer promotes best practice in the importance and benefit of using a Spacer with the manufacturers inclusion of one with the product.

R

Marketing Opportunities

This innovative solution creates an opportunity to engage with your customers, promoting your solutions, and inhaler best practice.
R

User-Friendly Design

Compared to other Spacers and using a pMDI alone, the MDI PLUS Spacer is easier to use, requiring fewer training sessions and minimizing mistakes during usage.

R

Durable Performance

The MDI PLUS Spacer maintains consistent aerosol properties even after multiple uses, ensuring reliable drug delivery over time.

R

Improved Lung Deposition

The Spacer enhances In-vivo lung deposition, ensuring a higher proportion of the medication reaches the target area, optimizing respiratory treatment outcomes.

R

Anti-Counterfeiting

Our MDI PLUS solution adds a layer of protection and additional control for manufacturers, through our patented design and our high-tech labelling technology.

Behind the scenes

The Innovation

There are approx. 3.2 million deaths due to chronic obstructive pulmonary disease (COPD) and 495,000 deaths due to asthma, according to the 2017 Global Burden of Diseases Study (GBD). Many millions more suffer from these diseases and would benefit from better drug delivery to the lungs, with the use of a Spacer.

MDI PLUS Ltd. is striving to alleviate this suffering and improve Patients’ lives, through this simple innovative solution.

Like all good innovations the simple ones are the best. MDI PLUS Ltd. discovered a solution to improve pMDI delivery and compliance. We carried out multiple, In-vivo and In-vitro tests and have now proved the hypothesis.

The MDI PLUS spacer is equivalent to the market leading plastic Spacer and is superior to using a pMDI alone.

Benefit your customers and enhance your product marketing with this innovative solution.

Improve Sustainability with MDI Plus.

Our Solution and its Results Compared

1

Lung Deposition

1

Ease of Use

1

Robustness

Lung Deposition

  • In-vitro equivalence to market leading plastic Spacer.
  • In-vivo superiority to pMDI alone (and equivalence to market leading Spacer)
  • Good in-use patient acceptability.

Summary of aerosol properties

Mean Value (n=3) pMDI (alone) AeroChamber MDI PLUS
Fine Particle Dose [µg] 91.47 130.33 126.74
MMAD [um] 4.15 4.22 3.88
GSD 1.63 1.48 1.37

Ease of Use

When testing the easiness of the use of pMDI(alone) with MDI PLUS compared to pMDI with Aerochamber and pMDI alone we found that pMDI with MDI PLUS required a lower number of sessions to use it correctly, have a lower number of correctly used steps mistakes compared to pMDI with Aerochamber and pMDI alone.

Number of sessions to correctly use of pMDI and pMDI with spacers (n=20)

pMDI(alone) Aerochamber MDI PLUS
Mean (SD) 2.15 (0.99) 2.05 (0.83) 1.05 (0.69)
Median 2 2 1
Total number of mistakes 104 135 19

Robustness

The MDI Plus was shown to deliver a similar amount of aerosol with similar properties after 20 and 50 uses.

Following extensive tests, the MDI Plus spacer was shown to continue to provide, improved performance, against using a measured dose inhaler alone.

Lung Deposition
  • In-vitro equivalence to market leading plastic Spacer.
  • In-vivo superiority to pMDI alone (and equivalence to market leading Spacer)
  • Good in-use patient acceptability.

Summary of aerosol properties

Mean Value (n=3) pMDI (alone) AeroChamber MDI PLUS
Fine Particle Dose [µg] 91.47 130.33 126.74
MMAD [um] 4.15 4.22 3.88
GSD 1.63 1.48 1.37
Ease of Use

Ease of Use

When testing the easiness of the use of MDI(alone) with MDI Plus compared to pMDI with Aerochamber and pMDI alone we found that pMDI with MDI PLUS required a lower number of sessions to use it correctly, have a lower number of correctly used steps mistakes compared to pMDI with Aerochamber and pMDI alone.

Number of sessions to correctly use of pMDI and pMDI with Spacers (n=20)

pMDI(alone) Aerochamber MDI Plus
Mean (SD) 2.15 (0.99) 2.05 (0.83) 1.05 (0.69)
Median 2 2 1
Total number of mistakes 104 135 19
Robustness

The MDI PLUS was shown to deliver a similar amount of aerosol with similar properties after 20 and 50 uses.

Following extensive tests, the MDI PLUS Spacer was shown to continue to provide, improved performance, against using a measured dose inhaler alone.

MDI PLUS Patient Benefits

R

Improved Medication Deposition

The MDI PLUS spacer enhances aerosol delivery and compensates for patient coordination issues, ensuring more of the medication reaches the patient’s lungs.

R

Reduced Systemic Side Effects

The Spacer effectively traps large particles that cause systemic side effects, leading to a decrease in infection side effects when using a pMDI with a Spacer.

R

Cost-Effectiveness

By using the carton box of the pMDI as the Spacer, the MDI PLUS Spacer reduces costs for patients and remains readily available whenever the pMDI is needed.

R

Sustainable

The MDI PLUS spacer, is very sustainable as it reduces the need for additional spending, ensures better medication delivery and as a result reduces overuse and waste.

R

Best Practice

Using any Spacer, reduces the amount of product being deposited in the mouth/throat and enhances better deposition of the medicine in the lungs.

R

Storage

Storing your inhaler in the box supplied, means you always have a Spacer available for emergencies.

How to use MDI PLUS Carton / Box Spacer

Step by Step Instructions:

  1. Open Inhaler carton at the top end of the carton, breaking seal/perforations, if it’s a new pack.
  2. Remove Inhaler and Patient Information Leaflet.
  3. Remove protective mouthpiece cap and check there is nothing inside Spacer or box.
  4. Shake the pMDI and insert into the end of the carton.
  5. Breath out as far as comfortable.
  6. With the carton closed, bring Spacer up to mouth.
  7. Depress the inhaler to release the dose at the start of inhalation.
  8. Maintain a slow inhalation rate until the lungs are full.
  9. Lower Spacer from the mouth and breathe hold for 5-10 seconds.
  10. If more than one dose is required, wait about 30 seconds, before the next dose.
  11. Replace Cap and store back in box / carton, in your jacket, bag or briefcase.
  12. MDI PLUS box can be used 50+ times.

About Us

David Little

MDI PLUS Ltd. – Managing Director

Print and Packaging Technologist and Independent Packaging Consultant

David has over 35 years’ experience, covering all packaging substrates, including cartons, corrugate, flexible film laminates, rigid plastics, labels and all printing and conversion processes. He is also experienced in Packaging Consultancy & Training, Sales & Marketing, New Product Development, Brand Management, Repro and Capital Equipment.

He has worked across all sectors, including Food & Drink, Pharmaceutical, IT, and Industrial.

David holds the following positions:

  • Managing Director of Leonard Little & Associates Ltd. www.leonardlittleassociates.com.
  • Chair of the Irish Packaging Society.
  • Board Member of ‘IOM3 – The Packaging Society’ (UK).
  • Course Director for multiple packaging training courses
  • Lecturer in Print & Packaging Technology in Ireland, UK and EU.
  • Fellow of the Institute of Materials, Minerals and Mining (IOM3).

Dr. Mohamed EA Abdelrahim

MDI Plus Ltd. – Director of Innovation

Received his PhD from Bradford University, Bradford, UK in 2009 in aerosol therapy. He is listed in the Sanford list of best researchers in the world since 2019 to the present day.

Mohamed has written over 200 published papers and over 80 conference presentations most of them in aerosol therapy. His main area of expertise is Clinical pharmacy and
aerosol

Get In Touch

How to Obtain A License

R

Our Intellectual Property is currently Patent Pending.

Our IP covers the innovation of using an Inhaler holder, carton or packaging by the addition of apertures or holes, allowing it to be used as a Spacer.

There is room within the IP for manufacturers to personalise the design, board, coatings or tamper evident aspects of the pack or holder.

Tel: +353 45 493406

Mobile: +353 87 9086 123

david@mdi-plus.com

MDI PLUS Ltd. Suite 3 & 4, ACEC, Woodstock Ind. Est., Kilkenny Road, Athy, Co Kildare. R14 T270, Ireland